Lv1
50 积分 2023-01-28 加入
Characterization of Anti-CD3 Antibodies in Clinically Available Bispecific T Cell Engagers
8个月前
已关闭
Human kallikrein 2: A novel lineage-specific surface target in prostate cancer
8个月前
已完结
Disrupting the balance between activating and inhibitory receptors of γδT cells for effective cancer immunotherapy
9个月前
已完结
Clinical Pharmacology Characterization and Dose Selection of Xaluritamig, a Next Generation XmAb® 2+1 T‐Cell Engager, in Prostate Cancer Patients
9个月前
已完结
Discovery and Phase 1 study of a novel monoclonal antibody against human IL-1β for the treatment of IL-1β-mediated diseases
9个月前
已完结
皖公网安备34019202002308
